Inorganic Chemistry, volume 59, issue 16, pages 11823-11833

BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.

Yao Houzong 1, 2
Shu Chen 1, 2
Deng Zhiqin 1, 2
Tse Man Kit 1
1
 
Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, People’s Republic of China
2
 
City University of Hong Kong Shenzhen Research Institute, Shenzhen 518057, People’s Republic of China
Publication typeJournal Article
Publication date2020-08-06
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor4.6
ISSN00201669, 1520510X
Inorganic Chemistry
Physical and Theoretical Chemistry
Abstract
Platinum drugs are widely used in clinics to treat various types of cancer. However, a number of severe side effects induced by the nonspecific binding of platinum drugs to normal tissues limit their clinical use. The conversion of platinum(II) drugs into more inert platinum(IV) derivatives is a promising strategy to solve this problem. Some platinum(IV) prodrugs, such as carboplatin-based tetracarboxylatoplatinum(IV) prodrugs, are not easily reduced to active platinum(II) species, leading to low cytotoxicity in vitro. In this study, we report the design and synthesis of a carboplatin-based platinum(IV) prodrug functionalized with a boron dipyrromethene (bodipy) ligand at the axial position, and the ligand acts as a photoabsorber to photoactivate the platinum(IV) prodrug. This compound, designated as BODI-Pt, is highly stable in the dark but quickly activated under irradiation to release carboplatin and the axial ligands. A cytotoxic study reveals that BODI-Pt is effective under irradiation, with cytotoxicity 11 times higher than that in the dark and 39 times higher than that of carboplatin in MCF-7 cells. Moreover, BODI-Pt has been proven to kill cancer cells by binding to the genomic DNA, arresting the cell cycle at the G2/M phase, inducing oncosis, and generating ROS upon irradiation. In summary, we report a green-light-activatable and carboplatin-based Pt(IV) prodrug with improved cytotoxicity against cancer cells, and our strategy can be used as a promising way to effectively activate carboplatin-based platinum(IV) prodrugs.

Citations by journals

1
2
3
4
5
Coordination Chemistry Reviews
Coordination Chemistry Reviews, 5, 12.2%
Coordination Chemistry Reviews
5 publications, 12.2%
Dalton Transactions
Dalton Transactions, 4, 9.76%
Dalton Transactions
4 publications, 9.76%
Angewandte Chemie
Angewandte Chemie, 3, 7.32%
Angewandte Chemie
3 publications, 7.32%
Angewandte Chemie - International Edition
Angewandte Chemie - International Edition, 3, 7.32%
Angewandte Chemie - International Edition
3 publications, 7.32%
Molecules
Molecules, 2, 4.88%
Molecules
2 publications, 4.88%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 2, 4.88%
International Journal of Molecular Sciences
2 publications, 4.88%
ACS applied materials & interfaces
ACS applied materials & interfaces, 2, 4.88%
ACS applied materials & interfaces
2 publications, 4.88%
Chemical Communications
Chemical Communications, 2, 4.88%
Chemical Communications
2 publications, 4.88%
Frontiers in Chemistry
Frontiers in Chemistry, 1, 2.44%
Frontiers in Chemistry
1 publication, 2.44%
European Journal of Medicinal Chemistry Reports
European Journal of Medicinal Chemistry Reports, 1, 2.44%
European Journal of Medicinal Chemistry Reports
1 publication, 2.44%
Bioorganic Chemistry
Bioorganic Chemistry, 1, 2.44%
Bioorganic Chemistry
1 publication, 2.44%
Current Opinion in Chemical Biology
Current Opinion in Chemical Biology, 1, 2.44%
Current Opinion in Chemical Biology
1 publication, 2.44%
Journal of Inorganic Biochemistry
Journal of Inorganic Biochemistry, 1, 2.44%
Journal of Inorganic Biochemistry
1 publication, 2.44%
Bioconjugate Chemistry
Bioconjugate Chemistry, 1, 2.44%
Bioconjugate Chemistry
1 publication, 2.44%
Inorganic Chemistry
Inorganic Chemistry, 1, 2.44%
Inorganic Chemistry
1 publication, 2.44%
ACS Nano
ACS Nano, 1, 2.44%
ACS Nano
1 publication, 2.44%
RSC Advances
RSC Advances, 1, 2.44%
RSC Advances
1 publication, 2.44%
Advances in Inorganic Chemistry
Advances in Inorganic Chemistry, 1, 2.44%
Advances in Inorganic Chemistry
1 publication, 2.44%
Science advances
Science advances, 1, 2.44%
Science advances
1 publication, 2.44%
ChemBioChem
ChemBioChem, 1, 2.44%
ChemBioChem
1 publication, 2.44%
Russian Chemical Reviews
Russian Chemical Reviews, 1, 2.44%
Russian Chemical Reviews
1 publication, 2.44%
Chemical Society Reviews
Chemical Society Reviews, 1, 2.44%
Chemical Society Reviews
1 publication, 2.44%
Biomolecules
Biomolecules, 1, 2.44%
Biomolecules
1 publication, 2.44%
Journal of Biological Inorganic Chemistry
Journal of Biological Inorganic Chemistry, 1, 2.44%
Journal of Biological Inorganic Chemistry
1 publication, 2.44%
1
2
3
4
5

Citations by publishers

2
4
6
8
10
Elsevier
Elsevier, 10, 24.39%
Elsevier
10 publications, 24.39%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 8, 19.51%
Royal Society of Chemistry (RSC)
8 publications, 19.51%
Wiley
Wiley, 7, 17.07%
Wiley
7 publications, 17.07%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 5, 12.2%
Multidisciplinary Digital Publishing Institute (MDPI)
5 publications, 12.2%
American Chemical Society (ACS)
American Chemical Society (ACS), 5, 12.2%
American Chemical Society (ACS)
5 publications, 12.2%
Frontiers Media S.A.
Frontiers Media S.A., 1, 2.44%
Frontiers Media S.A.
1 publication, 2.44%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 1, 2.44%
American Association for the Advancement of Science (AAAS)
1 publication, 2.44%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 2.44%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.44%
Springer Nature
Springer Nature, 1, 2.44%
Springer Nature
1 publication, 2.44%
2
4
6
8
10
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Yao H. et al. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity. // Inorganic Chemistry. 2020. Vol. 59. No. 16. pp. 11823-11833.
GOST all authors (up to 50) Copy
Yao H., Shu C., Deng Z., Tse M. K., Matsuda Y., Zhu G. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity. // Inorganic Chemistry. 2020. Vol. 59. No. 16. pp. 11823-11833.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1021/acs.inorgchem.0c01880
UR - https://doi.org/10.1021%2Facs.inorgchem.0c01880
TI - BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
T2 - Inorganic Chemistry
AU - Yao, Houzong
AU - Shu, Chen
AU - Deng, Zhiqin
AU - Matsuda, Yudai
AU - Zhu, Guangyu
AU - Tse, Man Kit
PY - 2020
DA - 2020/08/06 00:00:00
PB - American Chemical Society (ACS)
SP - 11823-11833
IS - 16
VL - 59
SN - 0020-1669
SN - 1520-510X
ER -
BibTex |
Cite this
BibTex Copy
@article{2020_Yao,
author = {Houzong Yao and Chen Shu and Zhiqin Deng and Yudai Matsuda and Guangyu Zhu and Man Kit Tse},
title = {BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.},
journal = {Inorganic Chemistry},
year = {2020},
volume = {59},
publisher = {American Chemical Society (ACS)},
month = {aug},
url = {https://doi.org/10.1021%2Facs.inorgchem.0c01880},
number = {16},
pages = {11823--11833},
doi = {10.1021/acs.inorgchem.0c01880}
}
MLA
Cite this
MLA Copy
Yao, Houzong, et al. “BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity..” Inorganic Chemistry, vol. 59, no. 16, Aug. 2020, pp. 11823-11833. https://doi.org/10.1021%2Facs.inorgchem.0c01880.
Found error?